Product
PanCytoVir
Aliases
PanCytoVir™ 100 mg/mL oral suspension
2 clinical trials
2 indications
Indication
Relative BioavailabilityIndication
COVID-19Clinical trial
A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 InfectionStatus: Completed, Estimated PCD: 2022-09-07